UroGen Pharma Ltd. Overview
Pro stress-test →UroGen Pharma is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers, developing RTGel reverse-thermal hydrogel technology enabling sustained drug release. The company's flagship product Jelmyto targets non-surgical tumor ablation in non-muscle invasive urothelial cancer, with investigational candidate UGN-102 in pivotal development.
Strategic Profile
Pro stress-test →UroGen's RTGel platform is a proprietary sustained-release hydrogel technology designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. The company recently secured a revised $250 million loan agreement with Pharmakon Advisors (signed February 26), providing $200 million to refinance existing debt and fund operations, with an additional $50 million available upon conditions.
Competitive Landscape
Pro stress-test →UroGen competes in the clinical-stage biopharmaceutical space focused on non-surgical treatment options for urological cancers. Primary competitors include larger oncology focused companies (Merck, Janssen) developing bladder cancer therapies and specialty biotech firms using alternative local delivery technologies.
Industry Context
UroGen Pharma Ltd. operates in Biopharmaceutical/Oncology - Urothelial Cancer Therapeutics.
Key facts
Founded: 2004 · Headquarters: Princeton, New Jersey, USA · Employees: 201 · Revenue: $96.5M · Market cap: $1.02B